Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment (2025)

Peer-Reviewed Study · Greenlee H, Crew KD, Maurer M, Kalinsky K, Cremers S, Naini A, Tsai WY, Shi Z, Brogan F, Hershman DL · November 19, 2025

Greenlee H et al., 2025-11-19: Phase I randomised, placebo-controlled crossover trial of CoQ10 with doxorubicin in breast cancer. CoQ10 at 300 mg/day raised serum levels without altering doxorubicin pharmacokinetics or causing adverse events; the trial closed early for slow accrual and tested no cardiac endpoint.

There were no clinically significant pharmacokinetic interactions between 300 mg/day CoQ10 and doxorubicin and no differences in TAC or adverse events during treatment and nontreatment periods.

Abstract, Results

Greenlee H et al., 2025-11-19: Phase I randomised, placebo-controlled crossover trial of CoQ10 with doxorubicin in breast cancer. CoQ10 at 300 mg/day raised serum levels without altering doxorubicin pharmacokinetics or causing adverse events; the trial closed early for slow accrual and tested no cardiac endpoint. Study type: randomized trial.